Body's GIP hormone and blood pressure after meals in healthy adults
Official title: Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals
Run by University Hospital, Gentofte, Copenhagen · NCT06934473 · Data updated 2026-11-12
Researchers will try to see if the body's GIP hormone changes blood pressure after a meal in healthy men and women using infusions and tilt tests.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 40 Years |
| Sex | All |
| Enrollment | 16 (estimated) |
| Sponsor | University Hospital, Gentofte, Copenhagen Academic / other |
| Locations | 2 sites (Copenhagen, Hellerup and 1 other locations) |
| Status | Recruiting |
| Started | May 21, 2025 |
| Main results expected | January 31, 2026 |
| Study ends | January 31, 2026 |
| Registry record updated | September 8, 2025 |
| Trial ID | NCT06934473 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy adults aged 18–40 with BMI 18.5–29.9 kg/m2 who are not taking antihypertensives, GLP-1RAs, SNRIs, or other interfering medications and who can attend multiple in-person visits are ideal candidates.
✕Probably not a fit
People with chronic kidney or liver disease, anemia, known autonomic disorders (such as POTS or orthostatic hypotension), those on antihypertensives or excluded medications, older adults, or those outside the BMI range are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, double-blinded, placebo-controlled crossover experiment with four separate experimental days per participant. Each day includes either a mixed meal or water, a continuous double-blinded infusion of GIP(3-30)NH2 (a GIP receptor antagonist), GIP(1-42), or placebo, and three head-up tilt tests to provoke postural blood pressure changes. Sixteen healthy men and women aged 18–40 with BMI 18.5–29.9 kg/m2 will take part, and investigators will record cardiovascular hemodynamics, hormone levels, and symptoms of hypotension. The design compares responses within participants to determine how endogenous GIP contributes to postprandial blood pressure regulation.
Why it matters
Potential benefit: If successful, the results could clarify how GIP affects meal-related drops in blood pressure and guide development of strategies to prevent or treat postprandial hypotension.
How similar studies have gone: Prior work shows incretin hormones (GIP and GLP‑1) can affect cardiovascular and metabolic responses after meals, but using a GIP receptor antagonist to alter postprandial blood pressure is relatively novel with limited human data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18-40 years 2. BMI between 18.5 and 29.9 kg/m2 (both included) 3. Informed consent Exclusion Criteria: 1. Allergy or intolerance to ingredients included in the mixed meal 2. History of Orthostatic Hypotension (OH) or Postural Orthostatic Tachycardia Syndrome (POTS) or other autonomic dysfunction at the discretion of the investigators 3. Anaemia (haemoglobin below normal range \<7.3 mmol/L for women and \<8.3 mmol/L for men) 4. Kidney disease (estimated glomerular filtration rate (eGFR) \<90 ml/min/1.73 m2) at screening 5. Known liver disease and/or elevated plasma alanine aminotransferase (ALT) \> three times the upper limit of normal at screening 6. Treatment with antihypertensives 7. Treatment with GLP-1RA (Glucagon-like Peptide-1 Receptor Agonist) 8. Treatment with SNRI (Serotonin and Noradrenalin Reuptake Inhibitor) or treatment within two weeks before the first experimental day 9. Any ongoing medication that the investigator evaluates would interfere with trial participation 10. Any physical or psychological condition that the investigator evaluates would interfere with trial participation, including any acute or chronic illnesses 11. Any concomitant disease or treatment that, at the discretion of the investigators, might jeopardize the participant's safety during the trial 12. Alcohol/drug abuse as per discretion of the investigators 13. Pregnancy or breastfeeding 14. Participation in any other clinical trial during the study period 15. Mental incapacity or language barriers that preclude adequate understanding or cooperation or unwillingness to comply with trial requirements or pr discretion of the investigator
Where it's running
-
Center for Clinical Metabolic Research
Copenhagen, Hellerup, Denmark Recruiting -
Center for Clinical Metabolic Research
Copenhagen, Hellerup, Denmark Not yet recruiting
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.